{"id":439748,"date":"2021-02-19T07:03:18","date_gmt":"2021-02-19T12:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439748"},"modified":"2021-02-19T07:03:18","modified_gmt":"2021-02-19T12:03:18","slug":"anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/","title":{"rendered":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Feb.  19, 2021  (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, \u201cClinical Trials for Rare Diseases: Challenges and Opportunities\u201d, at the Precision in Clinical Trials Virtual Summit (West Coast) on Wednesday, February 24<sup>th<\/sup> at 3:35 p.m. EST (12:35 p.m. PST). The Precision in Clinical Trials Virtual Summit (West Coast) takes place Feb 24<sup>th<\/sup>&#8211; 25<sup>th<\/sup> 2021.<\/p>\n<p>\n        <strong>About Anavex Life Sciences Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex\u2019s lead drug candidate, ANAVEX\u00ae2-73 (<em>blarcamesine<\/em>), recently completed successfully a Phase 2a clinical trial for Alzheimer\u2019s disease and a Phase 2 proof-of-concept study in Parkinson\u2019s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX\u00ae2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and\/or reverse the course of Alzheimer\u2019s disease. ANAVEX\u00ae2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson\u2019s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae2-73 for the treatment of Parkinson\u2019s disease. ANAVEX\u00ae3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer\u2019s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX\u00ae3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLEmkyj4xRzqk1bEUccRSArh1ArHz6sPsk8Vk219d6_ATzBjWHxA5L_0GdSErWlTYoFsxTmBQFnxEiityy1vA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.anavex.com<\/a>. You can also connect with the company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_BhEHLEWfk_9jqt0J5UALXpCES_YqKLabhnMfAFTRmbEtxtPw7EC4ioTOhGKj0Sa4fDgkoKnjPlZJmFN6S4dqQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter,<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a4rt9ohVmiKrrRQ90u97TaqEGEg67h_5MRWy_27MTv6YY400GT4PRtr57rXCwmTemYnO6bkNQ8y3-xLgXUCi-8XyHV3UyeZW1bj6wFkweC6ptQEGd5DO96JxwmgKaDc9kGCo9-vkG6eBKdND-UBG1A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YPrPgxjirJpzH3facIZanglVSC_bUzwv8zh4VuZqGXLsuLEbdTCnOKRXQppCFoqEUZVQBek1rlBuwA8P0RgSI93nDKrV5ic0U0at5sOWb5BLFgdTcO4VTgjhoGTMDXiX\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n<p align=\"justify\">\n        <strong>For Further Information:<\/strong>\n      <\/p>\n<p align=\"justify\">Anavex Life Sciences Corp.<br \/>Research &amp; Business Development<br \/>Toll-free: 1-844-689-3939<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oSfain30HeP6O7mD4t23BcdiMDlYst853eEmuRcC8JdSlHPzJamcivPP2o_2oFo2kSB3ynczVOEohsa7VkjCcQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@anavex.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Andrew J. Barwicki<br \/>Investor Relations<br \/>Tel: 516-662-9461<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NI2rLja6ljI5k29sNy4xy-dLRnokT-Hj8ZfEh-sJV1PcbyBOKsde_9-GR7fhZ1XqJlo0TXdDB8vsP4eVWBPS0f8vBkTFfrN07b28T5OMEcg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">andrew@barwicki.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2ada57d9-0f52-4323-93ee-45ce6d6c952f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, \u201cClinical Trials for Rare Diseases: Challenges and Opportunities\u201d, at the Precision in Clinical Trials Virtual Summit (West Coast) on Wednesday, February 24th at 3:35 p.m. EST (12:35 p.m. PST). The Precision in Clinical Trials Virtual Summit (West Coast) takes place Feb 24th&#8211; 25th 2021. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439748","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, \u201cClinical Trials for Rare Diseases: Challenges and Opportunities\u201d, at the Precision in Clinical Trials Virtual Summit (West Coast) on Wednesday, February 24th at 3:35 p.m. EST (12:35 p.m. PST). The Precision in Clinical Trials Virtual Summit (West Coast) takes place Feb 24th&#8211; 25th 2021. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) &hellip; Continue reading &quot;Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T12:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit\",\"datePublished\":\"2021-02-19T12:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/\"},\"wordCount\":534,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/\",\"name\":\"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\",\"datePublished\":\"2021-02-19T12:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/","og_locale":"en_US","og_type":"article","og_title":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk","og_description":"NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, \u201cClinical Trials for Rare Diseases: Challenges and Opportunities\u201d, at the Precision in Clinical Trials Virtual Summit (West Coast) on Wednesday, February 24th at 3:35 p.m. EST (12:35 p.m. PST). The Precision in Clinical Trials Virtual Summit (West Coast) takes place Feb 24th&#8211; 25th 2021. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) &hellip; Continue reading \"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T12:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit","datePublished":"2021-02-19T12:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/"},"wordCount":534,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/","name":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=","datePublished":"2021-02-19T12:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzNCMzOTg0OTgzIzIwMTk1Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439748"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}